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Abstract
We have developed a liquid chromatography/mass spec-
trometry (LC-MS/MS) assay to determine acrylamide in
various body fluids. The assay also allows the reliable
quantitation of acrylamide in food. In a total of 11 healthy
male and female subjects, we were able to show that
acrylamide from food given to humans is in fact ab-
sorbed from the gut. The half-lives determined in two
male subjects were 2.2 and 7 h. Acrylamide was found in
human breast milk and penetrated the human placenta
(n = 3). The variability of acrylamide concentrations
found in this investigation is most likely caused by vari-
able intersubject bioavailability and metabolism. This
may be an important indication that the assessment of
the risk from acrylamide for the individual may be very
difficult without knowing the concentrations of acrylam-
ide in the body. This should be considered in the design
of any risk assessment study or post hoc analysis of ear-
lier studies. At this time, we suggest that pregnant wom-
en and breast-feeding mothers avoid acrylamide-con-
taining food.
Copyright © 2002 S. Karger AG, Basel
Introduction
Previously, the risks involved in acrylamide exposure
were thought to be primarily related to high-volume use of
the monomer, the popular use of polyacrylamide products
in effluent and water treatment as a flocculant or exposure
of workers to acrylamide [1–4]. Also, its increasing use as
a grout raised concerns [1, 2]. Acrylamide has been identi-
fied as being carcinogenic, neurotoxic, genotoxic and a
category 3 reprotoxicant [5–13] in animals. Neurotoxic
effects have also been shown in humans, including the
nonfatal outcome of a deliberate ingestion of as much as
18 g of acrylamide crystals [14]. The patient in this report
suffered from severe neurotoxicity but survived. Practi-
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cally all of the information on acrylamide toxicity in
humans originates from inhalation and dermal uptake,
with occasional reports of deliberate uptake or accidental
uptake, e.g. of acrylamide in drinking water [15].
Recently, however, acrylamide has been identified to
occur in food [16–19]. That has led to worldwide efforts to
understand the mechanisms of its formation in food and
assess the risk to consumers. It was shown soon after that
observation that reducing sugars and amino acids, pre-
dominantly asparagine in starch-rich food and heating
beyond 140°C, lead to significant but also variable acryl-
amide formation [20, 21].
Authors of several studies suggested that acrylamide
toxicity may be related to the formation of a hemoglobin
adduct in animals [22–26] as well as in humans [27–30].
This adduct is considered a surrogate of toxicity since if
acrylamide can react with hemoglobin it should also be
able to react with other large molecules such as important
and functional proteins and DNA. Similarly, glycidam-
ide, the metabolite of acrylamide, may react with hemo-
globin. Although these reactions may be interrelated,
there has been no convincing evidence up to now that
hemoglobin adduct measurements may help to assess the
cancer risk of acrylamide in humans [31].
Acrylamide has been shown to be converted to glycid-
amide, the epoxide of acrylamide, by cytochrome P450
2E1 [32]. The involvement of cytochrome P450 enzymes
raises the question of polymorphic metabolism of the
chemical, possibly leading to variable toxic effects. How-
ever, at this time there is little evidence that acrylamide is
in fact governed by a polymorphic metabolism [33]. Oth-
er metabolic steps include formation of a glutathione con-
jugate. Most if not all information on the fate of acrylam-
ide in the body stems from in vitro studies and studies in
animals where it was given by oral, intravenous, intraperi-
toneal and dermal routes [34–36]. In humans, no data
have become available on the direct measurement of
acrylamide in blood, plasma, tissue and urine, except for
the case of intoxication mentioned above [14]. The only
other information on the uptake of acrylamide by humans
in a greater number of individuals comes from measure-
ment of hemoglobin adducts [27–30].
The limitation of using the measurement of hemoglo-
bin adduct data for assessing the fate of acrylamide in the
body is its site of formation. It seems that acrylamide pen-
etrates red blood cells readily, and formation of the
adduct occurs in a cellular compartment. This method
seems suitable to measure the chronic uptake of acrylam-
ide into the blood circulation. However, it cannot be used
to measure uptake of acrylamide in tissues of interest for
potential toxic effects of acrylamide. Finally, measure-
ment of these adducts is of no use to measure the toxicoki-
netics after ingestion of a ‘single dose’ of acrylamide by a
human individual. Hemoglobin adduct measurement is
therefore only of very limited value and will not contrib-
ute to the assessment of toxic effects in the tissues, not to
mention the fact that hemoglobin is not a site of acrylam-
ide toxicity.
Very recently, a report by Mucci et al. [37] released
information from a population-based case-control study
that was planned to assess the relationship between het-
erocyclic amines in fried food and cancer. The authors
claimed to have found no evidence that acrylamide in
amounts typically ingested in Sweden has any measurable
effect on the risk of three major types of cancer. That
study has major shortcomings that have been and certain-
ly will be discussed by the scientific community in the
very near future. Two major shortcomings of such studies
and in particular the conclusions from such a study that
are related to the work described here are presented.
Firstly, the relationship between ‘intake’ of acrylamide
and cancer risk was based entirely on data on the food
itself. Since no study has ever been done where it has in
fact been shown that acrylamide is absorbed from the gut,
this kind of data may only provide vague indications. The
bioavailability of acrylamide from different foods and in
different humans can be so different that the groups of
‘acrylamide intake’ formed in that study may not at all
reflect the quantitative intake precisely.
Secondly, the authors make a most misleading and
scientifically unsound case that acrylamide is ‘effectively
detoxified’. In subsequent media interviews with the first
author, this argument was further propounded [18]. There
is no pharmacological basis whatsoever for this unscien-
tific statement. Of greater concern, those arguments were
used to further support the most questionable conclusion
of the nonexistence of a cancer risk.
In any case, it is apparent that there is a lack of toxico-
kinetic data in humans and that it is most important that
such data are obtained. We report the results of a pilot
study of acrylamide in humans. Regular food was admin-
istered to a total of 13 humans. Acrylamide was analyzed
in urine and breast milk. Additionally, three fresh placen-
tas from three mothers were perfused with acrylamide
and the fetal concentration was assessed. This first inves-
tigation of the fate of acrylamide in the body became pos-
sible after successful development of the first bioanalyti-
cal methodology to analyze acrylamide in these matrices
by LC-MS/MS (tandem mass spectrometry).
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Subjects and Methods
Nine healthy male volunteers (18–52 years old) ate commercially
available food in amounts of up to 500 g of potato chips or crisp
bread. Urine samples were collected before and after food ingestion.
Two apparently healthy mothers ate about 100 g of self-prepared
potato chips (mother No. 1, age 33 years) and 100 g of commercially
available potato chips (mother No. 2, age 24 years). All subjects were
apparently healthy. The amount of acrylamide was estimated to be
about 1 mg in mother 1 and 800 Ìg in the other. The placentas used
for this investigation came from documented healthy mothers who
remained anonymous to the investigators.
The food listed in table 1 was prepared in a home kitchen and a
typical household setting from commercially available potato or car-
bohydrate, oil and fat sources. Preparation of food was done in a
regular household oven or microwave oven.
To evaluate the extent of placental transfer of acrylamide, an in
vitro perfused human postpartum placenta model was used. Three
human placentas were obtained following caesarean section. The
construction for the dual simultaneous perfusion of an isolated coty-
ledon consisted of two separate pump systems for the maternal and
fetal circuits, respectively, the perfusion chamber and thermostats to
control the temperature of the perfusion chamber and the perfusates.
The composition of the perfusates for the maternal and fetal sides of
the placenta was identical, i.e. TC medium 199, bovine albumin,
dextran and sodium bicarbonate in distilled water. However, acryl-
amide was added to the maternal perfusate to achieve a concentra-
tion close to 1 Ìg/ml. Before the start of the perfusion, the solutions
were heated to 37°C, gassed with carbogen (95% oxygen, 5% carbon
dioxide) and adjusted to a pH of 7.4 in order to establish approxi-
mately physiological conditions. During perfusion, the perfusates
and perfusion chamber were maintained at 37°C. Perfusates were
not recirculated. To establish the fetal circuit, cannulae were inserted
into both the fetal artery and fetal vein of a peripheral cotyledon. The
perfusion chamber contained a port for the influx of the fetal arterial
perfusate and a sampling port for the fetal venous perfusate. The
maternal arterial perfusate reached the intervillous space of the coty-
ledon through five catheters simulating the maternal endometrial
arterioles. The sampling port for the discharged maternal venous per-
fusate was located at the bottom of the perfusion chamber. Maternal
and fetal perfused samples were obtained from the separate sampling
ports after 1, 3, 5, 9, 15, 25 and 30 min during perfusion and stored
for analysis.
Measurement of acrylamide in urine, breast milk and placenta
perfusion medium by liquid chromatography/mass spectrometry
(LC-MS/MS) was performed as follows. Urine samples were thawed
and vigorously mixed. To 6 ml of urine sample 150 Ìl of internal
standard solution and buffer were added. Acrylamide was extracted
by liquid/liquid extraction and the organic solvent subsequently
evaporated to 200 Ìl under a stream of N2 at 35°C.
Placental perfusate samples were thawed and vigorously mixed.
To 0.25 ml of placental perfusate sample 50 Ìl of internal standard
solution and buffer were added. Acrylamide was extracted by liquid/
liquid extraction and the organic solvent subsequently evaporated to
200 Ìl under a stream of N2 at 35 °C.
Breast milk samples were thawed and vigorously mixed. To
2.5 ml of breast milk sample 50 Ìl of internal standard solution and
buffer were added. Acrylamide was extracted by liquid/liquid extrac-
tion and the organic solvent subsequently evaporated to 200 Ìl under
a stream of N2 at 35 °C.
Table 1. Acrylamide content of food
a Potato chips and French fries listed according to parameters studied for
influence on acrylamide formation
Sample Size, mm Cooking
temperature
°C
Cooking
time
min
Acrylamide
concentration
Ìg/kg
Potato chips 3 180 2 2,557.9
3 140 2 36.3
3 180 4 7,678.3
3 140 4 53.3
1 180 1 121.1
1 140 2 20.0
1 180 3 9,670.2
1 140 4 35.3
French fries 5 180 2 1,716.9
5 160 2 53.8
5 140 2 11.0
5 180 4 2,687.0
5 160 4 1,049.5
5 140 4 77.0
10 180 2 674.2
10 160 2 !8
10 140 2 !8
10 180 4 1,084.3
10 160 4 87.3
10 140 4 10.0
13 180 4 476.2
13 140 2 !8
13 180 6 880.0
13 140 4 !8
b Other foods
Sample Description Cooking
method
Cooking
time
min
Acrylamide
concentration
Ìg/kg
Walnuts – roasted – !8
Pine seeds – roasted – 16.4
Candied chestnuts – baked – 8.3
Crème caramel – boiled – !8
Whiskey – – – !8
Liver of beef – baked – !8
Breaded fish – baked – !8
Goose skin – oven – !8
Goose meat – oven – !8
Gingerbread lightly baked 200 °C – 12.1
dark baked 200 °C – 113.0
– – – 180.7
Gingerbread balls – – – 639.5
Spiced cookies – – – 143.6
Popcorn – mw, 800 W 1 29.7
– mw, 600 W 2 50.0
– mw, 800 W 2 132.8
– mw, 600 W 3 250.3
– mw, 600 W 4 307.1
Croquettes – 180 °C 2 354.7
– 180 °C 4 453.4
Hash browns – 180 °C 2 446.1
– 180 °C 4 751.7
Fried potatoes – – – 543.1
Croutons – baked – 27.8
Bread crust – – – 370.6
Toast – toasted – 54.1
mw = Microwave.
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20 Ìl of each sample were analyzed. Chromatographic separation
was performed using a reversed-phase column eluted with an isocrat-
ic solvent system consisting of water, acetic acid and an organic mod-
ifier and monitored by LC-MS/MS (acrylamide: m/z (mass to charge
ratio) 72 → m/z 55; internal standard: m/z 75 → m/z 58). Under
these conditions, acrylamide and the internal standard eluted after
approximately 1.9 min for placental perfusate and breast milk and
2.4 min for urine. The data acquisition was done by RAD (version
2.6, PE Sciex, Thornhill, Ont., Canada) and the data processing by
MacQuan (version 1.6, Perkin Elmer, Toronto, Canada, 1991–
1998).
Urine, placental perfusate or breast milk samples were measured
against a urine, placental perfusate or breast milk calibration row,
respectively. Calibration standards were prepared by adding the
appropriate volumes of standard solution of acrylamide to acrylam-
ide-free human urine, perfusate or breast milk. Concentrations were
obtained down to a concentration of 1 ng/ml for urine, 2 ng/ml for
placenta perfusate and 5 ng/ml for breast milk. Similar procedures
were used for food.
There was no interference observed for acrylamide or the internal
standard. Weighted linear regression (1/peak area ratio2) was per-
formed for calibration. Linearity of the calibration could be proven
between 1 and 100 ng/ml for urine, 2 and 1,000 ng/ml for placental
perfusate and 5 and 20 ng/ml for breast milk. Quantification levels
were identical with the lowest calibration levels.
Interassay precision of the SQCs (spiked quality controls) of
acrylamide were 1.1% (1,000 ng/ml), 3.3% (500 ng/ml), 3.1% (50 ng/
ml) and 6.1% (5 ng/ml), and the accuracy of the standards ranged
from 98.6 to 101.4%.
Results and Discussion
This study revealed many new insights into the acryl-
amide problem. Furthermore, it showed for the first time
the successful use of an LC-MS/MS assay to measure
unchanged acrylamide in the human body. Our newly
developed assay is suitable for analyzing acrylamide
down to concentrations as low as 1 ng/ml in urine, 5 ng/ml
in breast milk and 2 ng/ml in placental perfusate. The
range of linearity was up to 1,000 ng/ml. The assay proved
most reliable in many analyses. There was no interference
of any endogenous material, although acrylamide has a
very small molecular weight. Intra- and interday variation
were excellent. Experience with other subsequent samples
proved the high reliability of the assay. The assay was also
used in a modified form to analyze acrylamide in home-
made food. The LC-MS/MS technology also proved most
suitable during these analyses.
The findings in homemade food were most surprising
(table 1). To prepare food at home is by no means to avoid
acrylamide formation. On the contrary, it is most likely
that at home, when the temperature and duration of cook-
ing are arbitrary and where French fries or potato chips
are prepared to yield a brownish color, extremely high
Table 2. Urinary concentrations of acrylamide and amount excreted
within 8 h
Subject No. Calculated
concentration
ng/ml
Amount of
urine
g
Excretion
Ìg
Before food
1 BQL 142.3 –
2 BQL 350.0 –
3 BQL 152.8 –
4 2.04 531.2 1.084
5 BQL 618.4 –
6 0.659* 677.3 **
7 BQL 780.3 **
8 0.712* 474.7 0.338
9 BQL 330.2 –
After food
1 3.56 135.4 0.482
2 BQL 875.8 –
3 5.27 160.6 0.846
4 1.97 493.8 0.971
5 6.31 903.3 5.702
6 2.63 378.9 0.996
7 3.62 1,011.6 3.662
8 4.05 254.3 1.030
9 5.54 911 5.047
Dashes indicate no acrylamide excretion. BQL = Below quantifi-
cation level.
* Below quantification level, but clearly measurable peaks in
chromatogram; ** no calculation performed because BQL.
acrylamide contents of these foods are possible. To our
knowledge, the highest-ever reported content of 9,670 Ìg/
kg acrylamide was found in homemade potato chips of
1 mm after 3 min of heating at our institution. The diame-
ter of the food and temperature and duration of cooking
were the key parameters for any type of food prepared.
Also, when corn was prepared to yield popcorn at 600 W,
the duration of microwave treatment was important. It is
also of interest that German Christmas cookies, spiced
biscuits and gingerbread balls contained high amounts of
acrylamide. Any type of animal meat and skin contained
no or negligible amounts of acrylamide. Our data support
previous findings by others that acrylamide is formed in
foods that contain carbohydrates and asparagine and are
heated towards 180°C. Others have demonstrated that
the water content is an important factor. Thin slices for
potato chips lead to quick evaporation of water and make
ideal conditions for acrylamide formation.
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Table 3. Concentrations of acrylamide in fetal perfusate
Sampling
time
min
Concentration of acrylamide, ng/ml
experiment 1 experiment 2 experiment 3
Average
concentration
ng/ml
1 BQL BQL BQL –
3 11.86 38.00 31.91 27.26
5 182.2 100.2 70.74 117.7
9 382.8 105.1 73.07 187.0
15 323.0 118.1 72.97 171.3
25 339.5 114.0 70.23 174.6
30 300.6 107.6 63.61 157.3
The dash indicates that no calculation was possible. BQL = Below
quantification level (2.00 ng/ml).
Table 4. Concentrations of acrylamide in maternal perfusate
Sampling
time
min
Concentration of acrylamide, ng/ml
experiment 1 experiment 2 experiment 3
Average
concentration
ng/ml
1 BQL BQL BQL –
3 416.5 484.9 550.1 483.8
5 573.7 931.9 583.6 696.4
9 772.2 1,070 723.9 855.4
15 930.7 1,066 695.2 897.3
25 809.5 1,049 696.5 851.7
30 887.1 867.6 710.9 821.8
The dash indicates that no calculation was possible. BQL = Below
quantification level (2.00 ng/ml).
Table 5. Transfer of acrylamide across the placenta (%*)
Sampling
time
min
Penetration, %
experiment 1 experiment 2 experiment 3
Average
1 – – – –
3 2.8 7.8 5.8 5.5
5 31.8 10.8 12.1 18.2
9 49.6 9.8 10.1 23.2
15 34.7 11.1 10.5 18.8
25 41.9 10.9 10.1 21.0
30 33.9 12.4 8.9 18.4
Dashes indicate that no calculation was possible. * % of plasma
concentrations.
Table 6. Concentrations of acrylamide in breast milk
Sampling
time
h
Concentration of acrylamide in breast milk, ng/ml
mother 1 mother 2
Pre-dose BQL BQL
1 – BQL
3 10.6 –
4 18.8 4.86
8 – 3.17
BQL = Below quantification level; – = no sample.
Our study also shows that a prevention strategy may be
used by heating to clearly less than 180°C and making
prepared products very thick. This can most likely be
explained by reversing the effect of the factors of heat,
water content and diameter. However, food prepared in
this way is less likely to be acceptable in taste. Yet, our
investigations demonstrate that acrylamide prevention
programs and appropriate parameter control at home and
at industrial manufacturing sites are possible.
We tested another carbohydrate as a reaction partner
of asparagine, i.e. glycogen from liver of beef, and found
no appreciable acrylamide formation. This suggests that
not just any macromolecular carbohydrate is able to react
with asparagine. Glycogen is obviously not a source of
acrylamide formation.
Of the 9 subjects participating in the study (table 2),
acrylamide could be detected in 8. Subject 2 ate a very
small amount of potato chips (less than 100 g). The
amounts of acrylamide excreted in the urine were very
small in the other 8 volunteers. This does not, however,
suggest that the bioavailability from food ingestion was
small. In humans, probably more than 90% of acrylamide
is metabolized and only a small fraction is excreted
unchanged. Variability in urinary excretion of acrylamide
between subjects was very high, which may be caused by
high variability in oral bioavailability and/or hepatic me-
tabolism. In 2 subjects, we were able to determine a half-
life of acrylamide of 2.2 h in one case and 7 h in the other
(fig. 1). The half-life in subject 2 was hampered due to
some type of second peak phenomenon that is observed in
pharmacology for certain drugs. The data confirm that the
half-life of acrylamide in humans is short in some subjects
and intermediate in others. Clearly, the data demonstrate
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Fig. 1. Acrylamide excretion in two healthy
subjects. a Excretion of acrylamide during
the collection period. b Cumulative excre-
tion. The half-life of acrylamide was 7.0 h in
subject 1 and 2.2 h in subject 2. X = Sub-
ject 1; $ = subject 2.
that acrylamide is not an ultra-short half-life agent in
humans. Unlike the statement of Mucci et al. [37] that
there is fast clearance of acrylamide from the body, our
findings do not support the idea of quick elimination or
those authors’ conclusions that acrylamide has no carci-
nogenic effects because of fast excretion. The most impor-
tant result of our pilot study is that acrylamide is in fact
absorbed from food ingested by humans. This is, to our
knowledge, the first proof of the bioavailability of acryl-
amide from food in humans. The high variability of acryl-
amide levels in urine may be a first hint of the difficulties
that large population studies may face when attempting to
assess the risk of cancer. In addition, our data support the
criticism of the study of Mucci et al. [37] regarding their
use of general data on food content but no individual
human bioavailability data to assess the cancer risk in
humans. The issue may turn out to be a most complex one
involving individual and possibly genetic factors that
determine the metabolic fate of acrylamide. The variabili-
ty of the fate of acrylamide in humans during this study
also became apparent from the fact that 3 of our 9 subjects
had predose levels of acrylamide (table 2). Thus, these
subjects may be slow eliminators of acrylamide.
Of immediate consequence for the public are our find-
ings on the penetration of acrylamide into breast milk (ta-
bles 5 and 6). Predose levels in these mothers were not
measurable, since they did not consume any possibly con-
taminated food for 10 h prior to the dose. Based on a daily
consumption of 500 ml of breast milk, the intake can be as
high as 10 Ìg of acrylamide for a baby if the mother eats
highly acrylamide-loaded food like one of our mothers.
Even in the other mother, who ate smaller amounts of
potato chips, an intake of about 2 Ìg may be calculated. In
those cases, the dose for a 3-kg baby would be 3.3 and
0.66 Ìg/kg acrylamide, respectively. Estimations of the
cancer risk assume 10 in 1,000 cancer cases per 1 Ìg per
day. For chemically related agents like vinyl chloride, a
higher sensitivity of young individuals has been found in
animals [38]. The neurotoxicity of acrylamide is also high-
er in the young compared to older animals [39]. Exposing
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young humans to these amounts of acrylamide during
breast-feeding seems to be unacceptable. The significant
placental transfer of acrylamide (tables 3 and 4) is even
more concerning. The unborn may be exposed to unac-
ceptably high levels of acrylamide. In this population, the
neurotoxicity may present an even more immediate and
direct problem. It is well known that fetuses and new-
borns do not have a fully established blood-brain and
probably blood-CSF barrier [40]. Mothers consuming
high amounts of acrylamide-containing food pose a risk to
their children by significant prenatal transfer of acrylam-
ide and hence the risk of neurotoxicity. This continues
postnatally until breast-feeding is stopped.
In summary, our first-ever data on the toxicokinetics
of acrylamide in humans may have a significant impact
on the consumption of food containing acrylamide. First,
industrially prepared food may be superior to homemade
food when the latter is prepared without following the
rules derived from this and other investigations. The find-
ings in humans call for studies defining the factors that
cause the variabilities in acrylamide levels and hence
adverse effects of acrylamide. Until a possibly high indi-
vidual risk is known, consumption of acrylamide-contain-
ing food should be minimized. In pregnant and postpar-
tum breast-feeding mothers, acrylamide-containing food
must be omitted. In the general population, the high vari-
ability of the bioavailability of acrylamide and its metabo-
lism to the more toxic glycidamide may be the greatest
obstacle to assessing the risk of cancer or neurotoxicity
following acrylamide ingestion. More importantly, the
individual risks caused by variability of acrylamide levels
in the body – as was very clearly shown in the present
study – may be even more challenging to research on
acrylamide.
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